Is affordability a pipe dream?
Complexities in forecasting eligible cases and associated costs of cell and gene therapy
Read the articleRelated insight
The impact of medication adherence on total healthcare costs for commercially insured patients
A current perspective for patients with diabetes, hypertension, and hyperlipidemia
Emerging Medicare Advantage and Part D trends from 2024 financial statements
Medicare Advantage (MA) and Part D insurers are citing significant financial headwinds in earnings calls and the press. Statutory financial statements provide insights into emerging trends through year-end 2024.
Medicare price negotiation: Anchored drug prices in uncharted waters
Maximum Fair Price (MFP) Issue Brief 2

How will Medicaid Pay for Cell and Gene Therapies
Amid the development of new cell and gene therapies, we present some strategies that states have used to control costs and risk among their MCOs.

The evolution of biosimilars in the United States
Biosimilars recently have made significant strides toward greater acceptance and utilization since their first U.S. approval in 2015, although challenges persist.

Commercial drug trends: 2024 release
This report provides insights into pharmacy cost and utilization trends based on our analysis of the Milliman Consolidated Health Cost Guidelines Sources Database.
Controlling Rx costs: Top 5 reasons for a PBM RFP
Five reasons why RFPs with PBMs should be a regular practice to help control Rx costs.
Impact of the Inflation Reduction Act on plans seeking creditable coverage
The Inflation Reduction Act’s higher standards for retiree prescription drug plans may require plan sponsors to enrich benefits in 2025 for creditable coverage.
Average Manufacturer Price cap removal: Implications for state Medicaid programs
As a new federal law, effective in 2024, removes a cap on manufacturers' drug rebate amounts, we explore the implications for state Medicaid programs.